Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma

Sam A. Greenall, Shengnan C. Chen, Gordon Alton, Graham Beaton, Reghan Boelter, Mattie Casey, Ivan Babic, Zara C. Bruce, Daniel J. Garama, Rajesh Mukthavaram, Fabio C. Tucci, Satheesh B. Ravula, Ambrosio Lopez, Susan Knowles, Gregory D. Stein, Yuchen Li, Bennett Stork, Rochelle D’Souza, Ashwani Kumar, Ralf Kittler, Ann C.M. Tuma, Jann N. Sarkaria, Daniel J. Gough, Rodney A. Stewart, Santosh Kesari, Bryan W. Day, Terrance G. Johns

Open source

DOI: 10.64898/2026.10.14.759257
Published: 2026-10-20
Container: Not recorded
Publisher: openRxiv
Open access: unknown

Credibility signals

uncertain Score 60/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
cautionPublication version: Identified as a preprint; peer review and later versions may change the record. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.64898/2026.10.14.759257,
  title = {Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma},
  author = {Sam A. Greenall and Shengnan C. Chen and Gordon Alton and Graham Beaton and Reghan Boelter and Mattie Casey and Ivan Babic and Zara C. Bruce and Daniel J. Garama and Rajesh Mukthavaram and Fabio C. Tucci and Satheesh B. Ravula and Ambrosio Lopez and Susan Knowles and Gregory D. Stein and Yuchen Li and Bennett Stork and Rochelle D’Souza and Ashwani Kumar and Ralf Kittler and Ann C.M. Tuma and Jann N. Sarkaria and Daniel J. Gough and Rodney A. Stewart and Santosh Kesari and Bryan W. Day and Terrance G. Johns},
  year = {2026},
  doi = {10.64898/2026.10.14.759257},
  url = {https://doi.org/10.64898/2026.10.14.759257}
}

RIS

TY  - JOUR
TI  - Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma
AU  - Sam A. Greenall
AU  - Shengnan C. Chen
AU  - Gordon Alton
AU  - Graham Beaton
AU  - Reghan Boelter
AU  - Mattie Casey
AU  - Ivan Babic
AU  - Zara C. Bruce
AU  - Daniel J. Garama
AU  - Rajesh Mukthavaram
AU  - Fabio C. Tucci
AU  - Satheesh B. Ravula
AU  - Ambrosio Lopez
AU  - Susan Knowles
AU  - Gregory D. Stein
AU  - Yuchen Li
AU  - Bennett Stork
AU  - Rochelle D’Souza
AU  - Ashwani Kumar
AU  - Ralf Kittler
AU  - Ann C.M. Tuma
AU  - Jann N. Sarkaria
AU  - Daniel J. Gough
AU  - Rodney A. Stewart
AU  - Santosh Kesari
AU  - Bryan W. Day
AU  - Terrance G. Johns
PY  - 2026
DO  - 10.64898/2026.10.14.759257
UR  - https://doi.org/10.64898/2026.10.14.759257
ER  -

APA

Greenall, S. A., Chen, S. C., Alton, G., Beaton, G., Boelter, R., Casey, M., Babic, I., Bruce, Z. C., Garama, D. J., Mukthavaram, R., Tucci, F. C., Ravula, S. B., Lopez, A., Knowles, S., Stein, G. D., Li, Y., Stork, B., D’Souza, R., Kumar, A., Kittler, R., Tuma, A. C., Sarkaria, J. N., Gough, D. J., Stewart, R. A., Kesari, S., Day, B. W., & Johns, T. G. (2026). Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma. https://doi.org/10.64898/2026.10.14.759257

Source records

crossref · retrieved 2026-11-10T12:02:54.842Z